South Korea firm to invest $10m in Weizmann scientists‘ anti-cancer drug | Timesofisrael
An additional $2m will be invested by another Korean concern in a company that aims to make the use of ultrasounds easier, also set up by Weizmann’s Yeda technology transfer arm
Hinterlasse eine Antwort
Sie müssen... (sein)angemeldet sein um einen Kommentar zu schreiben.